Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The drug for which spending increased the most due to a price increase was Gilead’s HIV treatment Biktarvy. The company ...

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...

Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...